Premium
Autoimmune hemolytic anemia in solid organ transplantation—The role of immunosuppression
Author(s) -
Kanellopoulou Theoni
Publication year - 2017
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/ctr.13031
Subject(s) - medicine , autoimmune hemolytic anemia , immunosuppression , tacrolimus , immunology , rituximab , transplantation , lymphoproliferative disorders , hemolytic anemia , anemia , hemolysis , organ transplantation , immune system , antibody , lymphoma
Hemolysis after solid organ transplantation can be caused by both immune and non‐immune‐mediated mechanisms, and the evaluation must take into account issues distinctive to the post‐transplant period. Autoimmune hemolytic anemia usually occurs within the first year and has been attributed to immunosuppressive treatment, infections, or underlying post‐transplant lymphoproliferative disorder. Review of the literature revealed 59 cases with autoimmune hemolytic anemia mostly in children after liver transplantation. Almost all of the patients at the time of diagnosis received immunosuppression with tacrolimus, and first‐line treatment with steroids and/or intravenous immunoglobulin was ineffective for complete remission. Rituximab was used as second‐line treatment especially in patients with underlying lymphoproliferative disorders whereas sirolimus showed encouraging results.